Ligand-Receptor Interactions and Structure-Function Relationships in Off-Target Binding of the β 3 -Adrenergic Agonist Mirabegron to α 1A -Adrenergic Receptors.

The β 3 -adrenoceptor agonist mirabegron is available for the treatment of storage symptoms of overactive bladder, including frequency, urgency, and incontinence. The off-target effects of mirabegron include binding to α 1 -adrenoceptors, which are central in the treatment of voiding symptoms. Here, we examined the structure-function relationships in the binding of mirabegron to a cryo-electron microscopy structure of α 1A . The binding was simulated by docking mirabegron to a 3D structure of a human α 1A -adrenoceptor (7YMH) using Autodock Vina. The simulations identified two binding states: slope orientation involving 10 positions and horizontal binding to the receptor surface involving 4 positions. No interactions occurred with positions constituting the α 1A binding pocket, including Asp-106, Ser-188, or Phe-312, despite the positioning of the phenylethanolamine moiety in transmembrane regions close to the binding pocket by contact with Phe-288, -289, and Val-107. Contact with the unique positions of α 1A included the transmembrane Met-292 during slope binding and exosite Phe-86 during horizontal binding. Exosite binding in slope orientation involved contact of the anilino part, rather than the aminothiazol end, to Ile-178, Ala-103, and Asn-179. In conclusion, contact with Met-292 and Phe-86, which are unique positions of α 1A , accounts for mirabegron binding to α 1A . Because of its lack of interactions with the binding pocket, mirabegron has lower affinity compared to α 1A -blockers and no effects on voiding symptoms.